Halozyme to Report First Quarter 2024 Financial and Operating Results

Go back to Halozyme to Report First Quarter 2024 Financial and Operating Results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) Delayed: 107.20 +0.20 (0.19%)
Previous Close $107.00    52 Week High $18.39 
Open $107.96    52 Week Low $6.96 
Day High $108.23    P/E N/A 
Day Low $106.34    EPS $-0.58 
Volume 861,839